ATHE 6-K
Alterity Therapeutics Ltd (ATHE)
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM6-K
REPORTOF FOREIGN PRIVATE ISSUER
PURSUANTTO RULE 13a-16 OR 15d-163
UNDERTHE SECURITIES EXCHANGE ACT OF 1934
Forthe month of February 2025
AlterityTherapeutics Limited
(Name of Registrant)
Level 14, 350 Collins Street,Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicateby check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
ThisForm 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980and 333-228671) and ourRegistration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417and 333-250076)
ALTERITYTHERAPEUTICS LIMITED
(adevelopment stage enterprise)
The following exhibits are submitted:
| 99.1 | Proposed issue of securities - ATH |
|---|
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alterity Therapeutics Limited | |
|---|---|
| By: | /s/ Geoffrey P. Kempler |
| Geoffrey P. Kempler | |
| Chairman |
Date: February 24, 2025
2
Exhibit 99.1
| Appendix<br> 3B - Proposed issue of securities |
|---|
Announcement Summary
Entity name
ALTERITY THERAPEUTICS LIMITED
Announcement Type
New announcement
Date of this announcement
24/2/2025
The Proposed issue is:
A placement or other type of issue
Total number of +securities proposed to be issued for a placement or other type of issue
| ASX +security code | +Security description | Maximum Number of +securities to be issued |
|---|---|---|
| New class-code to be<br> confirmed | Options with exercise<br> price of $0.028 and expiring on 26 February 2027 | 10,179,688 |
Proposed +issue date
14/4/2025
Refer to next page for full details of the announcement
| Appendix 3B - Proposed issue of securities | 1 / 5 |
| --- | --- | | Appendix<br> 3B - Proposed issue of securities | | --- |
Part 1 - Entity and announcement details
1.1Name of +Entity
ALTERITY THERAPEUTICS LIMITED
We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.
If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).
| 1.2 Registered Number Type | Registration Number |
|---|---|
| ABN | 37080699065 |
1.3ASX issuer code
ATH
1.4The announcement is
New announcement
1.5Date of this announcement
24/2/2025
1.6The Proposed issue is:
A placement or other type of issue
| Appendix 3B - Proposed issue of securities | 2 / 5 |
| --- | --- | | Appendix<br> 3B - Proposed issue of securities | | --- |
Part 7 - Details of proposed placement or other issue
Part 7A - Conditions
7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?
Yes
7A.1a Conditions
| Approval/Condition | Date for determination | Is the date estimated or actual? | ** Approval received/condition met? |
|---|---|---|---|
| +Security holder approval | 31/3/2025 | Estimated |
Comments
Part 7B - Issue details
| Is<br> the proposed security a ‘New class’<br><br> (+securities in a class that is not yet quoted or <br><br> recorded by ASX) or an ‘Existing class’ <br><br> (additional securities in a class that is already<br><br> quoted or recorded by ASX)?<br><br> <br>New<br> class | Will<br> the proposed issue of this<br><br><br><br>+security<br>include an offer of attaching +securities?<br><br><br><br>No |
|---|
Details of +securities proposed to be issued
ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)
| Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1? | Will the entity be seeking quotation of the ‘new’ class of +securities on ASX?<br><br> <br>Yes |
|---|---|
| No | |
| ASX +security code | +Security description |
| --- | --- |
| New class-code to be confirmed | Options with exercise price of $0.028 and expiring on 26 February 2027 |
+Security type
Options
Number of +securities proposed to be issued
10,179,688
| Appendix 3B - Proposed issue of securities | 3 / 5 |
| --- | --- | | Appendix<br> 3B- Proposed issue of securities | | --- |
Offer price details
Are the +securities proposed to be issued being issued for a cash consideration?
No
Please describe the consideration being provided for the +securities
| Nil consideration |
|---|
Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities
0.000001
Will all the +securities issued in this class rank equally in all respects from their issue date?
Yes
Options details
| +Security currency | Exercise price | Expiry date |
|---|---|---|
| AUD - Australian Dollar | AUD 0.0028 | 26/2/2027 |
Details of the type of +security that will be issued if the option is exercised
ATH : ORDINARY FULLY PAID
Number of securities that will be issuedif the option is exercised
| One ordinary share |
|---|
Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.
| To be provided in<br> the Notice of Meeting announcement. |
|---|
Part 7C - Timetable
7C.1 Proposed +issue date
14/4/2025
Part 7D - Listing Rule requirements
7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?
Yes
7D.1aDate of meeting or proposed meeting to approve the issue under listing rule 7.1
31/3/2025
7D.2Is a party referred to in listing rule 10.11 participating in the proposed issue?
No
7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?
No ****
7D.4Will any of the +securities to be issued be subject to +voluntary escrow?
No
| Appendix 3B - Proposed issue of securities | 4 / 5 |
| --- | --- | | Appendix 3B- Proposed issue of securities | | --- |
Part 7E - Fees and expenses
7E.1 Will there be a lead manager or broker to the proposed issue?
No
7E.2 Is the proposed issue to be underwritten?
No
7E.4 Details of any other material feesor costs to be incurred by the entity in connection with the proposed issue
| This option issue<br> forms part of the MST Financial fee arrangement for the underlying share issue announced on 10 February 2025. The full fee comprises<br> 5.5% of funds raised up to A$30 million and 6% of funds raised over $40 million. It was also agreed to issue MST Financial (and/or<br> its nominees) one Broker Option for every $2 raised under the underlying share issue, up to a maximum of 10,179,688, which are the<br> securities proposed to be issued in this Appendix 3B. |
|---|
Part 7F - Further Information
7F.01 The purpose(s) for which the entityis issuing the securities
| Funds<br> will be used to accelerate regulatory activities, clinical and non-clinical development, and manufacture of drug to advance ATH434.<br> Funds will also be used to commence a business development process for potential partnering. |
|---|
7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?
No
7F.2 Any other information the entitywishes to provide about the proposed issue
| The<br> Company will be seeking shareholder approval for the issue of these options at an upcoming EGM. |
|---|
7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:
The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)
| Appendix 3B - Proposed issue of securities | 5 / 5 |
| --- | --- |